☰

366 Cervical Cancer Clinical Trials Recruiting Now (October 2026): Locally Advanced, Recurrent/Metastatic, IO, ADC, TIL — KEYNOTE-A18, PAROLA, eVOLVECervical, 9MW2821

Last updated: October 25, 2026

Answer a few questions to find clinical trials matched to your specific Cervical Cancer situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Find matching trials →

Current Clinical Trial Landscape

About cervical cancer:

Roughly 13,000 new cases per year in the US, ~600,000 worldwide. About 95% are HPV-associated, mostly squamous cell carcinoma (HPV-16 and HPV-18 are the dominant types). The remaining ~5% are HPV-independent and tend to behave more aggressively. The disease has a meaningful global burden in Asia-Pacific, sub-Saharan Africa, and Latin America where HPV vaccination + screening coverage is lower.

Active research areas in 2026:

Standard of care (2026): Early-stage (FIGO IA–IB1): radical hysterectomy or definitive chemoradiation. Locally advanced (IB3–IVA): cisplatin-based chemoradiation + brachytherapy + pembrolizumab during and after chemoRT (KEYNOTE-A18; FDA Jan 2024 label: FIGO 2014 stage III–IVA). Recurrent / metastatic, first-line: pembrolizumab + paclitaxel + carboplatin or cisplatin ± bevacizumab for PD-L1 CPS ≥1 (KEYNOTE-826, FDA Oct 2021). After progression on chemotherapy (including pembrolizumab regimens): tisotumab vedotin (Tivdak; FDA accelerated approval Sep 2021, full approval Apr 2024 per innovaTV 301). China: cadonilimab (PD-1/CTLA-4) is NMPA-approved after platinum (2022) and first-line with chemo ± bevacizumab (2025, COMPASSION-16).

Recruiting Trials by Treatment Setting

Locally Advanced (Curative Intent)

For FIGO stage IB3–IVA disease where chemoradiation + brachytherapy is the curative-intent treatment, now with immunotherapy additions per the 2024 KEYNOTE-A18 standard:

Recurrent or Metastatic — First-Line

For untreated metastatic or recurrent disease. KEYNOTE-826 established pembrolizumab + chemo ± bevacizumab as standard for PD-L1-positive (CPS ≥1) disease; trials test what comes next:

After Pembrolizumab / Post-Platinum

For patients who have progressed on pembrolizumab + chemo. ADC era is the dominant theme, with TROP2, Nectin-4, HER3, and PD-L1 targets now in Phase 3 or expanded Phase 2:

Cell Therapy and HPV-Targeted Approaches

Cellular therapy is emerging for cervical cancer because HPV viral antigens make these tumors uniquely targetable:

Trials by Treatment Approach

Checkpoint Inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4)

PD-1 inhibitors are now standard: pembrolizumab with chemo in 1L PD-L1-positive (CPS ≥1) recurrent/metastatic disease and added to chemoRT in high-risk (stage III–IVA) locally advanced disease; cemiplimab monotherapy after platinum is EU-approved (its US application was withdrawn). View all checkpoint inhibitor trials →

Bispecific Antibodies (PD-1/CTLA-4, PD-1/VEGF)

2026 is a major year for bispecific antibody Phase 3 readouts in cervical cancer. Cadonilimab, volrustomig, QL1706, and MEDI5752 are all PD-1/CTLA-4 bispecifics (in China, cadonilimab is already NMPA-approved after platinum since 2022 and first-line since 2025, and QL1706 received conditional approval for previously treated disease in Sept 2024); ivonescimab is a PD-1/VEGF bispecific. View all bispecific trials →

Antibody-Drug Conjugates (ADCs)

Tisotumab vedotin (Tivdak), a tissue factor-targeted ADC, was the first FDA-approved ADC for cervical cancer (accelerated approval September 2021; full approval April 2024 per innovaTV 301). Phase 3 trials now test next-generation TROP2 ADCs (sacituzumab tirumotecan / MK-2870, SKB264), Nectin-4 ADCs (9MW2821 — the same target class as enfortumab vedotin in bladder), and HER3 ADCs (HER3-DXd / patritumab deruxtecan). View all ADC trials →

TIL and Cellular Therapy

Tumor-infiltrating lymphocyte therapy (modeled on lifileucel in melanoma) is being tested in recurrent cervical cancer. HPV-specific T-cell receptor therapy is in earlier-phase development.

Showing selected notable trials. View all 366 recruiting interventional cervical cancer trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find cervical cancer clinical trials I'm eligible for?

Paste your medical summary into ClinTrialFinder to get AI-matched cervical cancer trials in minutes. The tool considers your FIGO stage, HPV status, histology (squamous cell vs adenocarcinoma), prior chemoradiation, and prior immunotherapy exposure.

Does HPV status affect cervical cancer treatment options?

Yes, increasingly. About 95% of cervical cancers are HPV-associated and tend to respond better to immunotherapy because HPV viral antigens make tumors more visible to the immune system. The ~5% that are HPV-independent are more aggressive and increasingly recognized as a separate prognostic group. Some 2026 trials stratify by HPV status; HPV-targeted therapies (vaccines, HPV-specific T cells) are HPV-specific by design.

What is the current standard of care for locally advanced cervical cancer?

Since KEYNOTE-A18 (FDA January 2024), the standard for high-risk locally advanced disease is cisplatin-based chemoradiation plus brachytherapy with pembrolizumab added during and after chemoRT; the FDA label covers FIGO 2014 stage III–IVA. Multiple Phase 3 trials in 2026 test similar designs with other PD-1 inhibitors (adebrelimab) and PD-1/CTLA-4 bispecifics (cadonilimab, volrustomig).

What options exist after progression on pembrolizumab + chemo?

Tisotumab vedotin (Tivdak), a tissue factor-targeted antibody-drug conjugate, received FDA accelerated approval in September 2021 and full approval in April 2024 (innovaTV 301), and is the established option after progression on chemotherapy, including pembrolizumab-containing first-line regimens. Phase 3 trials now test TROP2-targeted ADCs (sacituzumab tirumotecan / MK-2870), Nectin-4 ADCs (9MW2821, the enfortumab-vedotin target class moving from bladder into cervical), SHR-A2102, and other ADC classes in head-to-head comparisons against physician's-choice chemotherapy. TIL cell therapy (GT101) is in Phase 2 for heavily-pretreated patients.

Find Cervical Cancer Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your FIGO stage, HPV status, and treatment history.

Find Matching Trials